首页 > 市场调查报告书 > 医疗设备

生技设备癌症

市场调查报告书

商品编码

1560803

全球癌症肿瘤分析市场 - 2024 - 2031

Global Cancer Tumor Profiling Market - 2024 - 2031

出版日期: 2024年09月23日 | 出版商:

DataM Intelligence | 英文 181 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

简介目录

报告概述

全球癌症肿瘤分析市场在 2023 年达到 95 亿美元，预计到 2031 年将达到 191.5 亿美元，在 2024-2031 年预测期间复合年增长率为 9.4%。

肿瘤分析是一项实验室测试，用于检查构成肿瘤生物学和癌症生长基础的基因突变或其他变化。这些资讯可以帮助医生根据肿瘤概况制定个人化的治疗计划。肿瘤分析是肿瘤科医师用来确定患者肿瘤路径是否与可用的标靶治疗相符的技术。肿瘤分析可以深入分析导致癌症进展和治疗抗药性的肿瘤分子特征。

肿瘤分析，也称为生物标记测试，是对癌细胞进行详细且灵敏的实验室分析。该测试的目的是暴露特定的生物标记突变，并确定与任何发现的突变相符的标靶治疗。肿瘤分析可以帮助指导和确定最有效的治疗计划。肿瘤分析从取得肿瘤组织样本开始。通常透过核心活检收集组织。

市场动态：

司机

癌症盛行率增加

全球癌症肿瘤分析市场的需求是由多种因素所驱动的。癌症盛行率的上升推动了市场的成长。例如，根据 nih.gov 2023 年 1 月发表的一篇文章，预计美国将出现 1,958,310 例新癌症病例和 609,820 例癌症死亡。在经历了二十年的下降之后，从 2014 年到 2019 年，前列腺癌的发生率每年增加 3%，意味着新增病例增加了 99,000 例。

此外，根据wcrf.org 的数据，包括非黑色素瘤皮肤癌(NMSC) 在内，2022 年全球癌症病例数为19,976,499 例。男性女性 9,175,141 人。此外，根据 IARC 的数据，2022 年将有近 2,000 万新发癌症病例（包括非黑色素瘤皮肤癌 [NMSC]），同时有 970 万人死于癌症（包括 NMSC）。据估计，大约五分之一的男性或女性一生中会罹患癌症，而大约九分之一的男性和十二分之一的女性会死于癌症。肺癌是 2022 年最常被诊断出的癌症，导致近 250 万新病例，即全球八分之一的癌症之一（占全球所有癌症的 12.4%）。

限制

与程序相关的高成本、缺乏医疗基础设施、缺乏报销政策以及样本收集和储存条件的技术问题等因素预计将阻碍市场。

细分市场分析

全球癌症肿瘤分析市场根据癌症类型、技术类型、生物标记类型、应用、最终用户和地区进行细分。

下一代定序领域约占全球癌症肿瘤分析市场份额的48.9%

预计下一代定序领域将在预测期内占据最大的市场份额。在这个领域，技术进步将推动这个市场。

下一代定序（NGS），也称为大规模并行定序，是捕捉大量癌症基因组资讯的有效方法。大多数 NGS 技术都围绕着边合成边定序。每个待定序的 DNA 片段都与阵列结合，然后 DNA 聚合酶依序添加标记的核苷酸。高解析度相机捕获来自每个整合的核苷酸的讯号，并记录空间座标和时间。然后可以透过电脑程式推断每个点的序列，以产生连续的 DNA 序列，称为读数。

例如，2023 年 4 月，安捷伦科技公司宣布推出 Agilent SureSelect Cancer CGP Assay，专为多种实体肿瘤类型的体细胞变异分析而设计。泛癌症检测设计基于NGS面板，该面板包含全球领先的癌症资料库中的679个基因，并与主要临床癌症研究人员合作。

市场地理分析

北美约占全球癌症肿瘤分析市场份额的 43.6%

预计北美地区将在预测期内占据最大的市场份额。该地区癌症发病率的上升和技术进步有助于推动市场发展。

例如，根据 nih.gov 2024 年 1 月发表的一篇文章，预计美国将出现 2,001,140 例新癌症病例和 611,720 例癌症死亡。到 2021 年，癌症死亡率持续下降，由于吸烟的减少、某些癌症的早期发现以及辅助和转移治疗方案的改进，自 1991 年以来避免了超过 400 万人死亡。然而，这些成果受到十大癌症中六种发病率上升的威胁。

此外，2023 年9 月，决策医学领域的领导者Pillar Biosciences, Inc. 宣布在全球推出oncoReveal Core LBx，这是一种仅供研究使用(RUO) 的下一代测序(NGS) 试剂盒，旨在使实验室能够基于液体活检的泛癌肿瘤分析解决方案。

Tumor profiling is a laboratory test to check for gene mutations or other alterations that make up the tumor biology and underlie the cancer growth. This information can help physicians build a personalized treatment plan based on the tumor profile. Tumor profiling is the technology oncologists use to determine if the pathways of a patient's tumor match up with available targeted treatments. Tumor profiling allows for deep analysis of a tumor's molecular characteristics that are responsible for cancer progression and therapy resistance.

Tumor profiling, also known as biomarker testing, is a detailed and sensitive laboratory analysis of cancer cells. The purpose of this testing expose specific biomarker mutations and identify targeted therapies matched to any found mutations. Tumor profiling can help guide and identify the most effective treatment plan. Tumor profiling starts with obtaining a sample of tumor tissue. The tissue is usually collected through a core biopsy.

Market Dynamics: Drivers

Increasing prevalence of cancer

The demand for the global cancer tumor profiling market is driven by multiple factors. The rising prevalence of cancers propels the market growth. For instance, according to an article published by nih.gov in January 2023, 1,958,310 new cancer cases and 609,820 cancer deaths are projected to occur in the United States. Cancer incidence increased for prostate cancer by 3% annually from 2014 through 2019 after two decades of decline, translating to an additional 99,000 new cases.

Moreover, according to wcrf.org, including non-melanoma skin cancer (NMSC) there were 19,976,499 cancer cases in 2022. When NMSC was excluded, this number dropped to 18,741,966 cancer cases around the world in 2022. Of these, 9,566,825 were in men and 9,175,141 in women. Moreover, according to IARC, There were close to 20 million new cases of cancer in the year 2022 (including nonmelanoma skin cancers [NMSCs]) alongside 9.7 million deaths from cancer (including NMSC). The estimates suggest that approximately one in five men or women develop cancer in a lifetime, whereas around one in nine men and one in 12 women die from it. Lung cancer was the most frequently diagnosed cancer in 2022, responsible for almost 2.5 million new cases, or one in eight cancers worldwide (12.4% of all cancers globally).

Restraints

Factors such as high cost associated with the procedure, lack of healthcare infrastructure, lack of reimbursement policies, and technical issues in sample collection and storage conditions are expected to hamper the market.

Market Segment Analysis

The global cancer tumor profiling market is segmented based on cancer type, technology type, biomarker type, application, end-user, and region.

The segment next-generation sequencing accounted for approximately 48.9% of the global cancer tumor profiling market share

The next-generation sequencing segment is expected to hold the largest market share over the forecast period. In this segment, technological advancements would drive this market.

Next-generation sequencing (NGS), also known as massively parallel sequencing, represents an effective way to capture a large amount of genomic information about a cancer. Most NGS technologies revolve around sequencing by synthesis. Each DNA fragment to be sequenced is bound to an array, and then DNA polymerase adds labeled nucleotides sequentially. A high-resolution camera captures the signal from each nucleotide becoming integrated and notes the spatial coordinates and time. The sequence at each spot can then be inferred by a computer program to generate a contiguous DNA sequence, referred to as a read.

For instance, in April 2023, Agilent Technologies Inc. announced the launch of the Agilent SureSelect Cancer CGP Assay designed for somatic variant profiling for a broad range of solid tumor types. The pan-cancer assay design is based on an NGS panel comprising 679 genes globally curated from leading cancer databases and in partnership with key clinical cancer researchers.

Market Geographical Analysis

North America accounted for approximately 43.6% of the global cancer tumor profiling market share

North America region is expected to hold the largest market share over the forecast period. The rising incidence of cancer, and technological advancements, in this region, help to propel the market.

For instance, according to an article published by nih.gov in January 2024, 2,001,140 new cancer cases and 611,720 cancer deaths are projected to occur in the United States. Cancer mortality continued to decline through 2021, averting over 4 million deaths since 1991 because of reductions in smoking, earlier detection for some cancers, and improved treatment options in both adjuvant and metastatic settings. However, these gains are threatened by increasing incidence for 6 of the top 10 cancers.

Moreover, in September 2023, Pillar Biosciences, Inc., the leader in Decision Medicine, announced the global launch of oncoReveal Core LBx, a research-use-only (RUO) next-generation sequencing (NGS) kit designed to enable laboratories with a solution for liquid biopsy-based pan-cancer tumor profiling.

Market Segmentation

By Cancer Type

Lung Cancer

Prostate Cancer

Breast Cancer

Colorectal Cancer

Melanoma cancer

Others

By Technology Type

Immunoassays

Next-Generation Sequencing

Polymerase Chain Reaction

In-Situ Hybridization

Microarray

Others

By Biomarker Type

Genomics Biomarker

Protein Biomarker

Others

By Application

Research Applications

Clinical Applications

Diagnostics

Personalized Medicines

Others

By End-User

Hospitals

Diagnostic Centers

Research and Academic Institutions

Others

By Region

North America

U.S.

Canada

Mexico

Europe

Germany

U.K.

France

Spain

Italy

Rest of Europe

South America

Brazil

Argentina

Rest of South America

Asia-Pacific

China

India

Japan

South Korea

Rest of Asia-Pacific

Middle East and Africa

Market Competitive Landscape

The major global players in the global cancer tumor profiling market include Qiagen N.V, NeoGenomics Laboratories, Genomic Health Inc., Caris Life Sciences, Helomics Corporation, NanoString Technologies Inc., Sysmex Corporation, Ribomed Biotechnologies Inc., Roche Diagnostics and Illumina Inc. among others.

Key Developments

In May 2024, Foundation Medicine Inc. announced the U.S. launch of FoundationOne(R)RNA, a tissue-based RNA sequencing test for the detection of cancer-related fusions across 318 genes. FoundationOne RNA enables reporting of fusions in all solid tumors and may be valuable for detecting fusions in certain cancers, such as non-small cell lung cancer (NSCLC), pancreatic cancer, cholangiocarcinoma, sarcoma, thyroid cancer, and bladder cancer.

In November 2023, Illumina Inc. announced a new generation of its distributed liquid biopsy assay for genomic profiling. The new TruSight(TM) Oncology 500 ctDNA v2 (TSO 500 ctDNA v2) is a research assay that enables noninvasive comprehensive genomic profiling (CGP) of circulating tumor DNA (ctDNA) from blood when tissue testing is not available or to complement tissue-based testing.

Why Purchase the Report?

To visualize the global cancer tumor profiling market segmentation based on cancer type, technology type, biomarker type, application, end-user, and region, as well as understand key commercial assets and players.

Identify commercial opportunities by analyzing trends and co-development

Excel data sheet with numerous data points of global cancer tumor profiling market level with all segments.

PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.

Product mapping is available in Excel consisting of key products of all the major players.

The global cancer tumor profiling market report would provide approximately 51 tables, 54 figures, and 181 Pages.

Target Audience 2024

Manufacturers/ Buyers

Industry Investors/Investment Bankers

Research Professionals

Emerging Companies

1. Methodology and Scope

1.1. Research Methodology
1.2. Research Objective and Scope of the Report

2. Definition and Overview

3. Executive Summary

3.1. Snippet by Cancer Type
3.2. Snippet by Technology Type
3.3. Snippet by Biomarker Type
3.4. Snippet by Application
3.5. Snippet by End-User
3.6. Snippet by Region

4. Dynamics

4.1. Impacting Factors
- 4.1.1. Drivers
  - 4.1.1.1. Increasing Prevalence of Cancer
  - 4.1.1.2. Technological Advancements
  - 4.1.1.3. Government Initiatives and Fundings
- 4.1.2. Restraints
  - 4.1.2.1. High Costs of Procedure
  - 4.1.2.2. Lack of Healthcare Infrastructure
  - 4.1.2.3. Lack of Reimbursement Policies
  - 4.1.2.4. Technical Issues in Collecting Samples
- 4.1.3. Opportunity
- 4.1.4. Impact Analysis

5. Industry Analysis

5.1. Porter's Five Force Analysis
5.2. Supply Chain Analysis
5.3. Pricing Analysis
5.4. Regulatory Analysis
5.5. Unmet Needs
5.6. PESTEL Analysis
5.7. Patent Analysis
5.8. SWOT Analysis

6. By Cancer Type

6.1. Introduction
- 6.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Cancer Type
- 6.1.2. Market Attractiveness Index, By Cancer Type
6.2. Lung Cancer*
- 6.2.1. Introduction
- 6.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
6.3. Prostate Cancer
6.4. Breast Cancer
6.5. Colorectal Cancer
6.6. Melanoma Cancer
6.7. Others

7. By Technology Type

7.1. Introduction
- 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology Type
- 7.1.2. Market Attractiveness Index, By Technology Type
7.2. Immunoassays*
- 7.2.1. Introduction
- 7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
7.3. Next-Generation Sequencing
7.4. Polymerase Chain Reaction
7.5. In-Situ Hybridization
7.6. Microarray
7.7. Others

8. By Biomarker Type

8.1. Introduction
- 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Biomarker Type
- 8.1.2. Market Attractiveness Index, By Biomarker Type
8.2. Genomics Biomarker*
- 8.2.1. Introduction
- 8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
8.3. Protein Biomarker
8.4. Others

9. By Application

9.1. Introduction
- 9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
- 9.1.2. Market Attractiveness Index, By Application
9.2. Research Applications*
- 9.2.1. Introduction
- 9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
9.3. Clinical Applications
9.4. Diagnostics
9.5. Personalized Medicines
9.6. Others

10. By End-User

10.1. Introduction
- 10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
- 10.1.2. Market Attractiveness Index, By End-User
10.2. Hospitals*
- 10.2.1. Introduction
- 10.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
10.3. Diagnostic Centers
10.4. Research and Educational Institutions
10.5. Others

11. By Region

11.1. Introduction
- 11.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
- 11.1.2. Market Attractiveness Index, By Region
11.2. North America
- 11.2.1. Introduction
- 11.2.2. Key Region-Specific Dynamics
- 11.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Cancer Type
- 11.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology Type
- 11.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Biomarker Type
- 11.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
- 11.2.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
- 11.2.8. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
  - 11.2.8.1. The U.S.
  - 11.2.8.2. Canada
  - 11.2.8.3. Mexico
11.3. Europe
- 11.3.1. Introduction
- 11.3.2. Key Region-Specific Dynamics
- 11.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Cancer Type
- 11.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology Type
- 11.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Biomarker Type
- 11.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
- 11.3.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
- 11.3.8. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
  - 11.3.8.1. Germany
  - 11.3.8.2. UK
  - 11.3.8.3. France
  - 11.3.8.4. Italy
  - 11.3.8.5. Spain
  - 11.3.8.6. Rest of Europe
11.4. South America
- 11.4.1. Introduction
- 11.4.2. Key Region-Specific Dynamics
- 11.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Cancer Type
- 11.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology Type
- 11.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Biomarker Type
- 11.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
- 11.4.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
- 11.4.8. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
  - 11.4.8.1. Brazil
  - 11.4.8.2. Argentina
  - 11.4.8.3. Rest of South America
11.5. Asia-Pacific
- 11.5.1. Introduction
- 11.5.2. Key Region-Specific Dynamics
- 11.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Cancer Type
- 11.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology Type
- 11.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Biomarker Type
- 11.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
- 11.5.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
- 11.5.8. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
  - 11.5.8.1. China
  - 11.5.8.2. India
  - 11.5.8.3. Japan
  - 11.5.8.4. South Korea
  - 11.5.8.5. Rest of Asia-Pacific
11.6. Middle East and Africa
- 11.6.1. Introduction
- 11.6.2. Key Region-Specific Dynamics
- 11.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Cancer Type
- 11.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology Type
- 11.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Biomarker Type
- 11.6.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
- 11.6.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User

12. Competitive Landscape

12.1. Competitive Scenario
12.2. Market Positioning/Share Analysis
12.3. Mergers and Acquisitions Analysis

13. Company Profiles

13.1. Qiagen N.V *
- 13.1.1. Company Overview
- 13.1.2. Product Portfolio and Description
- 13.1.3. Financial Overview
- 13.1.4. Key Developments
13.2. NeoGenomics Laboratories
13.3. Genomic Health Inc.
13.4. Caris Life Sciences
13.5. Helomics Corporation
13.6. NanoString Technologies
13.7. Sysmex Corporation
13.8. Ribomed Biotechnologies Inc.
13.9. Roche Diagnostics
13.10. Illumina Inc. (*LIST NOT EXHAUSTIVE)

14. Appendix

14.1. About Us and Services
14.2. Contact Us

02-2729-4219

+886-2-2729-4219

License/价格

全球癌症肿瘤分析市场 - 2024 - 2031

Global Cancer Tumor Profiling Market - 2024 - 2031

市场动态：

目录

第 1 章：方法与范围

第 2 章：定义与概述

第 3 章：执行摘要

第 4 章：动力学

第 5 章：产业分析

第 6 章：按癌症类型

第 7 章：按技术类型

第 8 章：依生物标记类型

第 9 章：按申请

第 10 章：最终用户

第 11 章：按地区

第 12 章：竞争格局

第 13 章：公司简介

第 14 章：附录

Market Segmentation

By Cancer Type

By Technology Type

By Biomarker Type

By Application

By End-User

By Region

Key Developments

Why Purchase the Report?

Table of Contents

1. Methodology and Scope

2. Definition and Overview

3. Executive Summary

4. Dynamics

5. Industry Analysis

6. By Cancer Type

7. By Technology Type

8. By Biomarker Type

9. By Application

10. By End-User

11. By Region

12. Competitive Landscape

13. Company Profiles

14. Appendix